London, UK.: Elsevier. — 108 p.
Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.
Keynote.Epigenetic mechanisms in developmental programming of adult disease.
Man Chen and Lubo Zhang.
Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data.
Sorel Muresan, Plamen Petrov, Christopher Southan, Magnus J. Kjellberg, Thierry Kogej, Christian Tyrchan, Peter Varkonyi and Paul Hongxing Xie.
Gene to screen.
Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
Balaji M. Agoram and Oleg Demin.
Post screen.What makes a good drug target?
Isabella Gashaw, Peter Ellinghaus, Anette Sommer and Khusru Asadullah.
Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy.
Ellora Sen.
Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Francesco Bertolini, Paola Marighetti, Ines Martin-Padura, Patrizia Mancuso, Dana D. Hu-Lowe,
Yuval Shaked and Alberto D’Onofrio.
Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination.
Nagendra R. Hegde, Srinivas V. Kaveri and Jagadeesh Bayry.
Anglo-Saxon pharmacopoeia revisited: a potential treasure in drug discovery.
Frances Watkins, Barbara Pendry, Olivia Corcoran and Alberto Sanchez-Medina.
Drug development in the light of translational science: shine or shade?
Martin Wehling.
New perspectives in pharmacological treatment of mild persistent asthma.
Paolo Montuschi and Peter J. Barnes.